NCT ID | Study Title | Action |
---|---|---|
NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | View |
NCT03469726 | Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer | View |
NCT00709826 | APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer | View |
NCT04212026 | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. | View |
NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | View |
NCT00548626 | Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer | View |
NCT05149326 | KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. | View |
NCT03267966 | Margin Status After Pancreaticoduodenectomy for Cancer | View |
NCT03979066 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma | View |
NCT02121626 | The FOCCUS Study: ȯocusing on Cancers Chemotherapys' Untreated Symptoms" | View |
NCT05391126 | GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | View |
NCT03498326 | Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer | View |
NCT02779257 | Pasireotide Treatment for Neuroendocrine Tumor | View |
NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | View |
NCT01050426 | A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU) | View |
NCT05483257 | Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma | View |
NCT04482257 | Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. | View |
NCT02811666 | Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers | View |
NCT03213626 | Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma | View |
NCT01703026 | Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses | View |
NCT06423326 | Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer | View |
NCT02607826 | Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors | View |
NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors | View |
NCT04247126 | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors | View |
NCT00338026 | A Phase I Study of ECO-4601 in Patients With Advanced Cancer | View |
National Pancreatic Cancer Foundation provides access to clinical research studies. This information is provided by clinicaltrials.gov and is maintained by the National Library of Medicine (NLM). Neither NPCF nor the US government review or approve the safety and science of the studies on this website. Read the disclaimer for details.
NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.
The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.
Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved